Actithera is advancing next-generation radioligand therapies (RLTs) by combining cutting-edge medicinal chemistry with covalent targeting approaches. Its lead program is a best-in-class small molecule FAP-targeted RLT with broad potential in solid tumors and a large therapeutic window.
Location: Oslo (Norway) and Boston (US)
Board director: Debora Dumont
Board observer: Clément Salque
Website: